LASIX ORAL SOLUTION 10 MG
FUROSEMIDE : 10 MG · DIN 02224720 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is LASIX ORAL SOLUTION?
LASIX ORAL SOLUTION 10 MG contains FUROSEMIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02224720, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Mar-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LASIX ORAL SOLUTION used for?
LASIX ORAL SOLUTION ® (furosemide) is indicated for: • The treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease including, nephrotic syndrome, as well as other edematous states amenable to diuretic therapy. • The control of mild to moderate hypertension, used alone, or in combination with other antihypertensive agents in more severe cases. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controllable with LASIX ORAL SOLUTION alone.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is LASIX ORAL SOLUTION called?
The same molecule, FUROSEMIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FURORESE | Latin | Czechia |
| FURON | Latin | Czechia |
| DROLINA | Latin | Bahrain, Saudi Arabia |
| Frusemix-M | Latin | Australia |
| Lasix | Latin | Australia, Bahrain |
| APO-Frusemide | Latin | Australia |
| FUROSEMIDE-WGR | Latin | Australia |
| Dino-Retic | Latin | South Africa |
| FUSIX | Latin | Bahrain |
| Aquarid | Latin | South Africa |
| DURESAN | Latin | Morocco |
| Frusax | Latin | Australia |
| Frusemix | Latin | Australia |
| FURILAN | Latin | Morocco |
| FUROSEMID BBP | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02224720 |
|---|---|
| Brand name | LASIX ORAL SOLUTION |
| Generic / active ingredient | FUROSEMIDE : 10 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03CA01 FUROSEMIDE |
| AHFS class | 40:28.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Mar-2008 |
| Original market date | 1998-11-12 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02224720 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2224720 |
| Brand name | LASIX ORAL SOLUTION |
| Active ingredient / INN | FUROSEMIDE : 10 MG |
| ATC code | C03CA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C03 |
| AHFS class | 40:28.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SANOFI-AVENTIS CANADA INC |
How is it stored and handled?
null
How is it supplied?
Available in bottles of 120 mL.
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | ORAL |
| Packaging as described in the monograph | Available in bottles of 120 mL. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Is FUROSEMIDE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by HIKMA CANADA LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C03CA01 FUROSEMIDE. 21 of 73 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FUROSEMIDE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 00396788 |
| APO-FUROSEMIDE | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 00362166 |
| APO-FUROSEMIDE | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 00707570 |
| FUROSEMIDE INJ USP | 10 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00527033 |
| FUROSEMIDE INJECTION SDZ | 10 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02382539 |
| FUROSEMIDE INJECTION USP | 10 MG | SOLUTION | STERIMAX INC | MARKETED | DIN 02461404 |
| FUROSEMIDE INJECTION USP | 10 MG | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02480530 |
| FUROSEMIDE INJECTION USP | 20 MG / 2 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02384094 |
| FUROSEMIDE INJECTION, USP | 10 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02535882 |
| FUROSEMIDE SPECIAL INJECTION | 250 MG / 25 ML | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02527499 |
Who else supplies FUROSEMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FUROSEMIDE appears in 291 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does FUROSEMIDE cost around the world?
FUROSEMIDE is listed on 14 national price registers Nexara tracks, across 284 pack listings published on 13 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 10 | 81 | 03 Sep 2026 |
| South Africa | single exit price | 27 | 38 | 01 Sep 2026 |
| Australia | ex-manufacturer | 9 | 30 | 08 Sep 2026 |
| Czechia | max producer price (ex-factory) | 8 | 24 | 03 Sep 2026 |
| Saudi Arabia | public | 16 | 21 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 12 | 18 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 9 | 16 | 02 Sep 2026 |
| United Kingdom | hospital | 10 | 10 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 10 | 10 | 03 Sep 2026 |
| Luxembourg | reimbursement | 9 | 9 | 05 Sep 2026 |
| Morocco | PPV (public price) | 5 | 9 | 05 Sep 2026 |
| United Arab Emirates | public | 7 | 8 | 31 Aug 2026 |
| Bahrain | retail (max) | 4 | 8 | 01 Sep 2026 |
| Belgium | public | 1 | 1 | 01 Sep 2026 |
| Italy | ex-factory (classe H) | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.